Evogene Subsidiary Ag Plenus Partners with Bayer for Weed Control

TL;DR

**Evogene's Ag Plenus just inked a deal with Bayer for a new weed control solution!**

AI Summary

Evogene Ltd. announced on February 21, 2024, that its subsidiary, Ag Plenus Ltd., has entered into a Licensing and Collaboration Agreement with Bayer AG. This agreement focuses on the development of a new sustainable weed control solution, as detailed in a press release attached as Exhibit 99.1 to the 6-K filing.

Why It Matters

This collaboration could lead to innovative agricultural solutions, potentially impacting global food production and environmental sustainability through new weed control methods.

Risk Assessment

Risk Level: low — The filing reports a collaboration agreement, which is generally a positive development and does not inherently introduce significant new risks.

Key Players & Entities

• Evogene Ltd. (company) — Registrant and parent company
• Ag Plenus Ltd. (company) — Evogene's subsidiary entering the agreement
• Bayer AG (company) — Partner in the Licensing and Collaboration Agreement
• February 2024 (date) — Month of report
• February 21, 2024 (date) — Filing date and announcement date

FAQ

Filing Documents

• zk2431028.htm (6-K) — 12KB
• exhibit_99-1.htm (EX-99.1) — 15KB
• image00002.jpg (GRAPHIC) — 3KB
• image00003.jpg (GRAPHIC) — 3KB
• 0001178913-24-000670.txt ( ) — 35KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Evogene Ltd., or Evogene, today announces that its subsidiary, Ag Plenus Ltd., or AgPlenus entered into a Licensing and Collaboration Agreement with Bayer AG, or Bayer, for the development of a new sustainable weed control solution. A copy of the press release is attached as Exhibit 99.1to this Report of Foreign Private Issuer on Form 6-K, or this Form 6-K. This agreement grants Bayer an exclusive license for the development and commercialization of products developed within the collaboration. AgPlenus will be entitled to receive an upfront payment, ongoing research funding, milestone payments, and royalties based on future product sales, subject to certain conditions set forth therein. This Form 6-K contains "forward-looking statements" relating to future events. These statements may be identified by words such as "will", "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates", or words of similar meaning. For example, Evogene is using forward-looking statements in this Form 6-K when it discusses the eligibility to ongoing research funding, future milestone and royalty payments. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, and involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene's reports filed with applicable securities authorities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The content of this Form 6-K, excluding Exhibit 99.1, is incorporated by reference into the registration statements on Form F-3 (File No. 333-253300) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: February 21, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release: AgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control Solution

View Full Filing

View this 6-K filing on SEC EDGAR